JournalofViralHepatitis,2012,19,205–212doi:10.1111/j.1365-2893.2011.01494.x
Adherencetonucleos(t)ideanaloguesforchronichepatitisBinclinicalpracticeandcorrelationwithvirologicalbreakthroughs
W.Chotiyaputta,C.Hongthanakorn,K.Oberhelman,R.J.Fontana,T.LicariandA.S.F.Lok
DivisionofGastroenterologyandHepatology,DepartmentofInternalMedicine,UniversityofMichiganHealthSystem,AnnArbor,MI,USAReceivedFebruary2011;acceptedforpublicationMay2011
SUMMARY.Medicationadherenceisimportantforthesuc-
cessofnucleos(t)ideanalogue(NUC)treatmentforchronichepatitisB.TheaimsofthisstudyweretodetermineadherencetoNUCsandfactorsassociatedwithNUCadherenceandtocorrelateNUCadherencewiththeoccurrenceofvirologicalbreakthroughsinpatientswithchronichepatitisB.ConsecutivepatientswithchronichepatitisBreceivingNUCwereaskedtocompleteasurveyevery3months.Adherencewasalsoassessedbyhealth-careprovidersintheclinic.Adherenceratewasde nedasthepercentofdaysthepatientstooktheirhepatitisBvirusmedicationsduringthelast30days.Atotalof111patientswerestudied.Themeanagewas47.7years,73.9%weremen,57.7%wereAsian,42.3%hadpost-graduateeducationand80%hadprivateinsurance.Sixty-nine(74.1%)patientsreported100%adherenceinthesurvey,while78(83.9%)reported100%adherenceto
theirhealthcareproviders.Patientswith100%adherencebasedonthesurveywereolder(P=0.02),morelikelytobemen(P=0.006),andhadhigherannualhouseholdincome(P=0.04)thanthosewith<100%adherence.Inthe80patientswhocompletedthreesurveys,viralbreak-throughwasobservedin1/46(2.2%)with100%adher-enceonallthreesurveys,1/18(5.6%)with<100%adherenceononesurveyand3/16(18.8%)with<100%adherenceon 2surveys,(P=0.06).Inconclusion,adherencetoNUCtherapyinourpatientswithchronichepatitisBwashighbutself-reportingofadherencetohealthcareprovidersmaybein ated.PatientswithchronichepatitisBwithbetteradherencetoNUCtherapyhadatrendtowardsalowerrateofviralbreakthroughs.Keywords:antiviralresistance,antiviraltherapy,HBVDNA,hepatitisBtreatment.
INTRODUCTION
Therearesevenapprovedtherapiesincluding venucle-os(t)ideanalogues(NUCs)andtwointerferonalphaformu-lationsforthetreatmentofchronichepatitisB(CHB).NUCshavepotentantiviralactivity,areadministeredorallyandhaveveryfewsideeffectsbuttheydonoteradicatehepatitisBvirus(HBV).Therefore,mostofthepatientsrequirelongdurationsoftreatmenttomaintainviralsuppressionandtoachieveclinicalbene t.Longdurationoftreatmentisasso-ciatedwithincreasingriskofdrugresistance.AnalysisofphaseIIIclinicaltrialsofNUCsfoundthatvirologicalbreakthrough(VBT)occurredin1.6–13.8%ofpatientsafter
Abbreviations:CHB,chronichepatitisB;GR,genotypicresistance;HBV,hepatitisBvirus;HIV,Humanimmunode ciencyvirus;NUCs,nucleos(t)ideanalogues;VBT,virologicbreakthrough.
Correspondence:AnnaS.F.Lok,MD,DivisionofGastroenterology,UniversityofMichiganHealthSystem,3912TaubmanCenter,SPC5362,1500EastMedicalCenterDrive,AnnArbor,MI48109,USA.E-mail:aslok@med.umich.edu
1yearoftreatment;however,genotypicresistance(GR)wasnotcon rmedinanyofthepatientswhoexperiencedVBTwhilereceivingNUCsthathavehighgeneticbarriertoresistance,suchasentecavirandtenofovir[1–7].TheseresultssuggestthatamajorcauseofVBTmaybepooradherencetomedications.
Medicationadherencehasbeenshowntocorrelatewithclinicalresponseandtreatmentoutcomeinmanymedicalconditions[8–12].Studiesinpatientsreceivingnonboostedproteaseinhibitor-basedregimensforhumanimmunode -ciencyvirus(HIV)infectionfoundthatnear-perfectadher-ence( 95%)wasrequiredtomaintainviralsuppressionandtopreventdrugresistance,whereasmoderatetohighlevelsofadherence(70–95%)tonon-nucleosidereversetrans-criptaseinhibitor-basedregimenswassuf cientforoptimalvirologicalresponse[12–15].Similarly,hypertensivepatientswithatleast80%adherencetoantihypertensiveagentswerelesslikelytodevelopcoronaryarterydisease,cerebrovasculardiseaseandcongestiveheartfailure,andhypercholesterolaemicpatientswithatleast90%adherencetostatinshadfewernonfatalcoronaryarteryevents[9,10].
Ó2011BlackwellPublishingLtd
(a) sequence of EBM followed by QI; (b) EBM uses clinical knowledge to...adherence to nucleos(t)ide analogue treatment for chronic hepatitis B》 ...
Chronic hepatitis B (CHB) infection is associated...ve nucleos(t)ide analogues and two interferon-...adherence to standard infection control precautions....
Antiviral resistance and poor adherence are the ...nucleos(t)ide analogues (NAs) for chronic ... treated by lamivudine for chronic hepatitis B. ...
hepatitis B: summary of a clinical research ...qualitatively in acute and chronic hepatitis B ...Nucleos(t)ide Analogues Only Induce Temporary ...
Keywords: Hepatitis B virus, pegylated interferon, nucleos(t)ide analogues,...relationship between these viral factors and clinical outcomes of chronic HBV ...
Nucleos(t)ide Analogues Nucleos(t)ide analogues are oral agents that can ...EASL Clinical Practice Guidelines: management of chronic hepatitis B. J ...
Nucleos(t)ide analogues can be safely discontinued in chronic hepatitis B patients achieving HBsAg seroclearance. Journal of Hepatology 2011; 54: S302-303...
Influence of prior exposure to nucleos(t)ide analogues .J Hepatol, 2010;...monotherapy in chronic hepatitis B:a single centre clinical practice experience...
hepatitis B: summary of a clinical research ...qualitatively in acute and chronic hepatitis B ...Nucleos(t)ide Analogues Only Induce Temporary ...
Nucleos(t)ide Analogues in Clinical Practice Chanunta Hongthanakorn, Watcharasak...and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. ...
热门文档